Medicarpin is a bioactive pterocarpan that has been attracting increasing attention in recent years. However, its metabolic fate in vivo is still unknown. To clarify its metabolism and the distribution of its metabolites in rats after oral administration, the HPLC-ESI-IT-TOF-MS n technique was used. A total of 165 new metabolites (13 phase I and 152 phase II metabolites) were tentatively identified, and 104, 29, 38, 41, 74, 28, 24, 15, 42, 8, 10, 3, and 17 metabolites were identified in urine, feces, plasma, the colon, intestine, stomach, liver, spleen, kidney, lung, heart, brain, and thymus, respectively. Metabolic reactions included demethylation, hydrogenation, hydroxylation, glucuronidation, sulfation, methylation, glycosylation, and vitamin C conjugation. M1 (medicarpin glucuronide), M5 (vestitol-1'-O-glucuronide) were distributed to 10 organs, and M1 was the most abundant metabolite in seven organs. Moreover, we found that isomerization of medicarpin must occur in vivo. At least 93 metabolites were regarded as potential new compounds by retrieving information from the Scifinder database. This is the first detailed report on the metabolism of ptercarpans in animals, which will help to deepen the understanding of the metabolism characteristics of medicarpin in vivo and provide a solid basis for further studies on the metabolism of other pterocarpans in animals.
Introduction
Pterocarpans are the second largest group of dihydroisoflavonoids and have a special structure skeleton (benzopyran-benzofuran four-ring system). They were originally isolated from plants [1] and then regarded as an important group of phytoalexins, which have antifungal [2] and antibacterial [3] effects. In recent years, many new bioactivities of pterocarpans have been discovered, such as anti-inflammation [4] [5] [6] , antitumor activity [7] [8] [9] , anti-osteoporosis [10] [11] [12] , antimalarial [13] , antioxidant [14] [15] [16] , inhibition of neuraminidase [17] [18] [19] and melanin synthesis [20] , estrogenic and anti-estrogenic activity [21] , anti-clastogensis [22] , immunosuppressive activity [23] , and inhibition of acetylcholinesterase [24] . As a result, this group of natural products is getting more and more attention. However, after conducting a systematic literature survey, we surprisingly found that there is only one report on the metabolism of a pure pterocarpan (i.e., trifolirhizin) in animals and only two metabolites (maackiain in feces and maackiain, maackiain-3-O-sulfoacid in urine) were identified [25] , though a lot 
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MS Fragmentation Characteristics of Medicarpin in ESI− Mode and Identification of Medicarpin in Rats
In order to facilitate the description of the ESI− MS characteristics of medicarpin and its metabolites, we proposed a nomenclature for the fragmentation pathways and fragment ions. The four rings were named A, B, C and D, respectively. The cleavable C-C bonds in the skeleton were designated by numbers 1-8, as shown in 
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MS Fragmentation Characteristics of Medicarpin in ESI− Mode and Identification of Medicarpin in Rats
Profiling 165 Metabolites of Medicarpin in Rats
The metabolites of medicarpin were screened by comparing the HPLC chromatograms and MS base peak chromatograms (BPCs) of drug and blank group samples obtained through HPLC-ESI-IT-TOF-MS n analysis, and then confirmed by comparison of extracted ion chromatograms (EICs) between the drug and blank groups. The metabolic reactions were judged by the accurate mass (elemental composition) differences between medicarpin and its metabolites. The accurate mass (elemental composition) differences of −14.01 Da (CH2), +14.01 Da (CH2), +2.01 Da (H2), and +15.99 Da (O) indicated demethylation, methylation, hydrogenation and hydroxylation. The loss of 176.03 Da (C6H8O6) from precursor ion and/or an anion at m/z 175.02 in MS 2 spectra indicated that the metabolite was a glucuronide; the loss of 79.95 Da (SO3) from precursor ion indicated that the metabolite was a sulfate; the loss of 162.05 Da (C6H10O5) indicated a hexoside (more likely to be a glucoside); the loss of 158.02 Da (C6H6O5) indicated a vitamin C conjugate [35] .
A total of 165 metabolites of medicarpin were confirmed and tentatively identified by the abovementioned method, and the proposed metabolic pathways of medicarpin are shown in Figure 3 . 
The metabolites of medicarpin were screened by comparing the HPLC chromatograms and MS base peak chromatograms (BPCs) of drug and blank group samples obtained through HPLC-ESI-IT-TOF-MS n analysis, and then confirmed by comparison of extracted ion chromatograms (EICs) between the drug and blank groups. The metabolic reactions were judged by the accurate mass (elemental composition) differences between medicarpin and its metabolites. The accurate mass (elemental composition) differences of −14.01 Da (CH 2 ), +14.01 Da (CH 2 ), +2.01 Da (H 2 ), and +15.99 Da (O) indicated demethylation, methylation, hydrogenation and hydroxylation. The loss of 176.03 Da (C 6 H 8 O 6 ) from precursor ion and/or an anion at m/z 175.02 in MS 2 spectra indicated that the metabolite was a glucuronide; the loss of 79.95 Da (SO 3 ) from precursor ion indicated that the metabolite was a sulfate; the loss of 162.05 Da (C 6 H 10 O 5 ) indicated a hexoside (more likely to be a glucoside); the loss of 158.02 Da (C 6 H 6 O 5 ) indicated a vitamin C conjugate [35] .
A total of 165 metabolites of medicarpin were confirmed and tentatively identified by the above-mentioned method, and the proposed metabolic pathways of medicarpin are shown in Figure 3 .
According to the skeleton of molecules, 165 metabolites were classified into 13 categories: (1) metabolites (M1-M3) having the skeleton of medicarpin; (2) metabolites (M4-M10) having the skeleton of hydrogenated medicarpin; (3) metabolites (M11-M26) having the skeleton of demethylated medicarpin; (4) metabolites (M27-M52) having the skeleton of demethylated and hydrogenated medicarpin; (5) metabolites (M53-M75) having the skeleton of demethylated and hydroxylated medicarpin; (6) metabolites (M76-M107) having the skeleton of hydroxylated medicarpin; (7) metabolites (M108-M138) having the skeleton of hydrogenated and hydroxylated medicarpin; (8) metabolites (M139-M149) having the skeleton of demethylated, hydrogenated and hydroxylated medicarpin; (9) metabolites (M150-M156) having the skeleton of demethylated and dihydroxylated medicarpin; (10) metabolites (M157-M161) having the skeleton of dihydroxylated medicarpin; (11) metabolite (M162) having the skeleton of hydrogenated and dihydroxylated medicarpin; (12) metabolites (M163-M164) having the skeleton of hydrogenated and trihydroxylated medicarpin; (13) O 10 , so they were isomers. The fragment ions at m/z 269.08 and m/z 175.02 can be detected in both of their MS 2 spectra. Therefore, M1 and M2 were determined to be glucuronides of medicarpin. However, medicarpin only has one hydroxyl group, i.e., one glucuronidation site (Figure 4a ). Hence, we deduced that isomerization of medicarpin (configuration change or shift of substituent) must occur.
M3 ( Figure 5) and their molecular formulae were predicted to be C22H22O10, so they were isomers. The fragment ions at m/z 269.08 and m/z 175.02 can be detected in both of their MS 2 spectra. Therefore, M1 and M2 were determined to be glucuronides of medicarpin. However, medicarpin only has one hydroxyl group, i.e., one glucuronidation site (Figure 4a ). Hence, we deduced that isomerization of medicarpin (configuration change or shift of substituent) must occur.
M3 ( Figure 5) 
Analysis of Metabolites (M4-M10) Having the Skeleton of Hydrogenated Medicarpin
.0979, and its molecular formula was predicted to be C16H16O4, which had two more hydrogen atoms than that of medicarpin. Therefore, one ring of medicarpin must be cleaved. In its MS 2 spectra, the fragment ions at m/z 147.0469 (C9H7O2, 6 3, 4 A − or 3,4 B − ), we could deduce that medicarpin had undergone ring cleavage at the bond of C11-C11a as shown in Figure 6a . Hence, M4 was determined to be vestitol. The characteristic fragment ion at m/z 135.05 (C8H7O2) was very useful, because its existence indicated that the C11-C11a bond was cleaved and the hydrogenated medicarpin had the skeleton of a vestitol. The MS 2 spectrum of M4 is shown in Figure S45 .
M5 and M6 showed [M − H] − at m/z 447.13, and their molecular formulae were predicted to be C22H24O10. Moreover, the fragment ions at m/z 271.09, m/z 175.02, m/z 147.05 (C9H7O2, 6 A − or 3,5 B − − 2H) and m/z 135.05 (C8H7O2, 3, 4 A − or 3,4 B − ) could be detected in their MS 2 spectra. Based on m/z 135.05 (C8H7O2), we could deduce that the ring-cleavage took place at the bond of C11-C11a. Because a larger CLogP value means a lower polarity and a larger retention time in reversed phase HPLC, so M5 (CLogP = 0.7229, tR = 90.033) was assigned as vestitol-1'-O-glucuronide and M6 (CLogP = 0.9229, tR = 92.050) was vestitol-7-O-glucuronide.
M8 and M9 showed [M − H] − at m/z 429.12 and their molecular formulae were predicted to be C22H22O9, and they yielded a fragment ion at m/z 271.09 by neutral loss of 158.02 Da (C6H6O5). In their MS 3 spectra, the characteristic fragment ions at m/z 147.05 (C9H7O2, 6 3, 4 A − or 3,4 B − ) and m/z 121.0354 (C7H5O2) were detected in MS 3 spectra. This indicated that M10 was a hydrogenated medicarpin glucuronide sulfate. Besides, based on m/z 135.0498 (C8H7O2), we could deduce that the bond of C11-C11a in medicarpin was cleaved. Moreover, the fragment ion at m/z 254.9829 (C10H7O6S,), which was derived from precursor ion m/z 527.0901, indicated that the sulfonic group (-SO3H) was linked to the fragment of C10H7O3 ( 1,5 B − − 4H), and the fragment ion at m/z 229.0156 (C9H9O5S), which was obtained from precursor ion m/z 351.0505, indicated that -SO3H was linked to the fragment of C9H9O2 ( 3,5 B − ). Hence, we could deduce that the sulfonic group was linked to the hydroxyl group of B ring, while the glucuronyl group was linked to the hydroxyl group of A ring. Therefore, M10 was unambiguously identified as vestitol-7-O-glucuronide-1'-O-sulfate. The MS spectra of M10 are shown in Figure S46 . 3, 4 B − ), we could deduce that medicarpin had undergone ring cleavage at the bond of C11-C11a as shown in Figure 6a . Hence, M4 was determined to be vestitol. The characteristic fragment ion at m/z 135.05 (C 8 H 7 O 2 ) was very useful, because its existence indicated that the C11-C11a bond was cleaved and the hydrogenated medicarpin had the skeleton of a vestitol. The MS 2 spectrum of M4 is shown in Figure S45 .
M5 and M6 showed [M − H] − at m/z 447.13, and their molecular formulae were predicted to be C 22 ), we could deduce that the bond of C11-C11a in medicarpin was cleaved. Moreover, the fragment ion at m/z 254.9829 (C 10 H 7 O 6 S,), which was derived from precursor ion m/z 527.0901, indicated that the sulfonic group (-SO 3 H) was linked to the fragment of C 10 H 7 O 3 ( 1,5 B − − 4H), and the fragment ion at m/z 229.0156 (C 9 H 9 O 5 S), which was obtained from precursor ion m/z 351.0505, indicated that -SO 3 H was linked to the fragment of C 9 H 9 O 2 ( 3,5 B − ). Hence, we could deduce that the sulfonic group was linked to the hydroxyl group of B ring, while the glucuronyl group was linked to the hydroxyl group of A ring. Therefore, M10 was unambiguously identified as vestitol-7-O-glucuronide-1'-O-sulfate. The MS spectra of M10 are shown in Figure S46 . Demethylated medicarpin only has two metabolism sites (two free hydroxyl groups), but it has three glucuronidation metabolites (M11-M13), seven sulfation metabolites (M14-M20) and three glucuronidation and sulfation metabolites (M21-M23). Therefore, we can confirm that isomerization of medicarpin (configuration change or shift of substituent) must occur. Demethylated medicarpin only has two metabolism sites (two free hydroxyl groups), but it has three glucuronidation metabolites (M11-M13), seven sulfation metabolites (M14-M20) and three glucuronidation and sulfation metabolites (M21-M23). Therefore, we can confirm that isomerization of medicarpin (configuration change or shift of substituent) must occur. , we could deduce that the skeleton of C 8 H 7 O 2 had two hydroxyl groups and the sulfonic group was linked to the B ring. As a result, the aglycon of M37 must be Q. The characteristic fragment ions of M27 and M37 are shown in Figure 7 . The MS spectrum of M37 is shown in Figure S47 . , we could deduce that the skeleton of C8H7O2 had two hydroxyl groups and the sulfonic group was linked to the B ring. As a result, the aglycon of M37 must be Q. The characteristic fragment ions of M27 and M37 are shown in Figure 7 . The MS spectrum of M37 is shown in Figure S47 . , M53 was determined to be demethylated and hydroxylated medicarpin. However, due to the special structure of the demethylated medicarpin, it is impossible to judge the position of hydroxylation based on the current mass spectrometry data.
Analysis of Metabolites (M27-M52) Having the Skeleton of Demethylated and
Analysis of Metabolites (M76-M107) Having the Skeleton of Hydroxylated Medicarpin
The molecular formulae of M87-M99 were predicted to be C 16 , M53 was determined to be demethylated and hydroxylated medicarpin. However, due to the special structure of the demethylated medicarpin, it is impossible to judge the position of hydroxylation based on the current mass spectrometry data.
The molecular formulae of M87-M99 were predicted to be C16H14O8S due to the pseudomolecular ion peak [M − H] − at m/z 365.04. In their MS 2 spectra, the fragment ion at m/z 285.08 (C16H13O5) formed by the loss of 79.95 Da (SO3) was detected. Therefore, M87-M99 were hydroxylated medicarpin sulfates. at m/z 287.0943 and the molecular formula was calculated to be C16H16O5, which was two hydrogen atoms and one oxygen atom more than that of medicarpin. Therefore, we speculated that M112 was hydrogenated and hydroxylated medicarpin. In its MS 2 spectra, a characteristic fragment ion at m/z 125.0181 (C6H5O3, 2,5 A − + 2H) was observed, indicating that the newly added hydroxyl group was linked to the A ring, so it has three possibilities O, P or Q. Besides, based on the fragment ion at m/z 151.0451 (C8H7O3, 3, 4 A − ), we could determine that the bond of C11-C11a was cleaved. Finally, the structure of M112 was determined to be O. Furthermore, the fragment ions of M112 including m/z 163.0388 (C9H7O3, 6 A − − H), m/z 149.0532 (C9H9O2, 3,5 B − ), m/z 145.0348 (C9H5O2, 6 A − − H − H2O), m/z 137.0334 (C7H5O3, 2,4 A − or 3,5 A − ) and m/z 134.0482 (C8H6O2, 3,5 B − − CH3•) supported our elucidation. The MS 2 spectrum of M112 is shown in Figure S48 . O 5 , which was two hydrogen atoms and one oxygen atom more than that of medicarpin. Therefore, we speculated that M112 was hydrogenated and hydroxylated medicarpin. In its MS 2 spectra, a characteristic fragment ion at m/z 125.0181 (C 6 H 5 O 3 , 2,5 A − + 2H) was observed, indicating that the newly added hydroxyl group was linked to the A ring, so it has three possibilities O, P or Q. Besides, based on the fragment ion at m/z 151.0451 (C 8 H 7 O 3 , 3,4 A − ), we could determine that the bond of C11-C11a was cleaved. Finally, the structure of M112 was determined to be O. Furthermore, the fragment ions of M112 including m/z 163.0388 (C 9 H 7 O 3 , 6 , we determined that the aglycon of M114 should be O or P. Moreover, based on the fragment ion at m/z 135.0094 (C7H3O3), we could deduce that the aglycon of M114 was O2 or P. However, because the same fragment ions could be produced from O2 or P, it was impossible to judge the position of hydroxylation based on the current mass spectrometry data. In addition, the elemental composition of m/z 229.0108 (C9H9O5S) suggested that the sulfonic group was connected to the fragment ion of m/z 149.0653 (C9H9O2). Hence, we could determine the sulfate was linked to the hydroxyl group of B ring. The MS 2 spectrum of M114 is shown in Figure S49 . , we could deduce that the aglycon of M114 was O2 or P. However, because the same fragment ions could be produced from O2 or P, it was impossible to judge the position of hydroxylation based on the current mass spectrometry data. In addition, the elemental composition of m/z 229.0108 (C 9 H 9 O 5 S) suggested that the sulfonic group was connected to the fragment ion of m/z 149.0653 (C 9 H 9 O 2 ). Hence, we could determine the sulfate was linked to the hydroxyl group of B ring. The MS 2 spectrum of M114 is shown in Figure S49 . . We therefore confirmed that the sulfonic group was linked to the hydroxyl group of B ring. The probable structure and characteristic fragment ions of M115 are shown in Figure 11 . The MS 2 spectrum of M115 is shown in Figure S50 . was cleaved. Moreover, m/z 230.9941 was predicted to be C8H7O6S, which indicated that the sulfonic group was connected to the fragment ion of m/z 151.0440 (C8H7O3, 3,4 B − ). We therefore confirmed that the sulfonic group was linked to the hydroxyl group of B ring. The probable structure and characteristic fragment ions of M115 are shown in Figure 11 . The MS 2 spectrum of M115 is shown in Figure S50 . . Based on the fragment ion at m/z 151.0428 (C8H7O3), we could deduce that the aglycon of M144 might be O, P, Q, R, S or T. According to the fragment ion at m/z 147.0451 (C9H7O2), we could exclude P, R and T. Besides, based on the fragment ion at m/z 137.0308 (C7H5O3), we could exclude E. Therefore, we could determine that the aglycon of M144 was O or Q. Furthermore, based on the fragment ion at m/z 147.0451 (C9H7O2), we finally deduced that the aglycon of M144 was O1, O2 or Q (Figure 12 ). The MS 2 spectrum of M144 is shown in Figure S51 . , we could deduce that the aglycon of M144 might be O, P, Q, R, S or T. According to the fragment ion at m/z 147.0451 (C 9 H 7 O 2 ), we could exclude P, R and T. Besides, based on the fragment ion at m/z 137.0308 (C 7 H 5 O 3 ), we could exclude E. Therefore, we could determine that the aglycon of M144 was O or Q. Furthermore, based on the fragment ion at m/z 147.0451 (C 9 H 7 O 2 ), we finally deduced that the aglycon of M144 was O1, O2 or Q (Figure 12 ). The MS 2 spectrum of M144 is shown in Figure S51 .
The molecular formulae of M147-M149 were predicted as C 21 
Analysis of Metabolites (M150-M156) Having the Skeleton of Demethylated and Dihydroxylated Medicarpin
M150-M151 showed [M − H]
− at m/z 463.09 and the molecular formulae were calculated to be C21H20O10. M152-M156 showed [M − H] − at m/z 367.01, indicating the molecular formulae of C15H12O9S. In their MS 2 spectra, the fragment ion at m/z 287.06 (C15H11O6) was detected. Compared with C16H14O4 of medicarpin, it had a less CH2 and two more oxygen atoms. As a result, medicarpin might undergo demethylation and dihydroxylation. Therefore, M150-M151 were glucuronides of demethylated and dehydroxylated medicarpin, while M152-M156 were sulfates of demethylated and dehydroxylated medicarpin. 2 and two more oxygen atoms. As a result, medicarpin might undergo demethylation and dihydroxylation. Therefore, M150-M151 were glucuronides of demethylated and dehydroxylated medicarpin, while M152-M156 were sulfates of demethylated and dehydroxylated medicarpin. 3 •) suggested that one hydroxyl group must be linked to the D ring. Furthermore, according to the fragment ion at m/z 203.9750 (C 6 H 4 O 6 S), we could determine that the sulfonic group was linked to the hydroxyl group of D ring. The fragmentation pathways of M159 are shown in Figure 13 . The MS spectrum of M159 is shown in Figure S52 . Figure 13 . The MS spectrum of M159 is shown in Figure S52 . 
Analysis of Metabolites (M157-M161) Having the Skeleton of Dihydroxylated Medicarpin
M157-M159
Analysis of Metabolites (M150-M156) Having the Skeleton of Demethylated and Dihydroxylated Medicarpin
M150-M151 showed [M − H]
Analysis of Metabolites (M157-M161) Having the Skeleton of Dihydroxylated Medicarpin
M157-M159
Analysis of Metabolites M162 Having the Skeleton of Hydrogenated and Dihydroxylated Medicarpin
Its molecular formula was calculated to be C16H16O6 based on [M − H] − at m/z 303.0861. Compared with the C16H14O4 of medicarpin, it had two more hydrogen atoms and two more oxygen atoms. Accordingly, M162 was determined as hydrogenated and dihydroxylated medicarpin. 
Its molecular formula was calculated to be C 16 2 and one more oxygen atom. Therefore, M165 was determined as a demethylated, hydrogenated and dihydroxylated medicarpin sulfate.
Distribution of 165 Metabolites in Rats
The distribution of 165 metabolites (including 104 metabolites in urine, 29 metabolites in feces, 38 metabolites in plasma, 41 metabolites in the colon, 74 metabolites in the intestine, 28 metabolites in the stomach, 24 metabolites in the liver, 15 metabolites in the spleen, 42 metabolites in the kidney, 8 metabolites in the lung, 10 metabolites in the heart, 3 metabolites in the brain and 17 metabolites in the thymus) of medicarpin and their relative contents in each biological sample are shown in Figure 14 . The relative content of a metabolite in each biosample was calculated by (peak area of a metabolite in the sample/total peak area of all metabolites detected in the sample) × 100%. The peak area of a metabolite was calculated from its extracted ion chromatogram.
From Figure 14 , we could find that: (1) in urine, M159 (12.68%, dihydroxylated medicarpin sulfate), M63 (11.86%, demethylated and hydroxylated medicarpin sulfate), M17 (7.18%, demethylated medicarpin sulfate), and M64 (5.34%) were four major metabolites and all of them were sulfates; it is an interesting phenomenon that sulfates other than glucuronides are major metabolites in urine, and the cause is unclear; (2) in feces, M18 (20.34%), M43 (10.35%), M34 (9.89%), M40 (8.86%), M3 (7.57%, Vc conjugate), and M27 (7.25%) were six major metabolites with a relative content higher than 5%, and three of them (M43, M34, M40) were demethylated and hydrogenated medicarpin sulfates; (3) in plasma, M1 (36.15%, medicarpin glucuronide), M5 (12.82%, vestitol-1'-O-glucuronide), M18 (10.81%), M65 (8.00%),and M40 (5.58%) were major metabolites; (4) M1 was the most abundant metabolite in the stomach, liver, spleen, kidney, lung, heart, and thymus. M5, M14 (demethylated medicarpin) were the most abundant metabolites in intestine and liver, respectively. M17 (demethylated medicarpin sulfate) was the most abundant metabolite in the colon and brain; (5) M1, M5 were detected in all 10 organs; M30 (demethylated and hydrogenated medicarpin glucuronide) was detected in nine organs (except the brain); M12 and M27 were detected in eight organs; therefore, these five metabolites were widely distributed in vivo. Considering the high abundance and wide distribution, we suggest that the bioactivities of these metabolites deserve further research in order to fully explain the pharmacological action mechanism of medicarpin. In addition, the reason for specific distribution of some metabolites (e.g., M2, M14, M20, M35, M40, M54, M109) also need further investigation.
The metabolic reactions of medicarpin included demethylation, hydrogenation, hydroxylation, glucuronidation, sulfation, glycosylation, methylation, and conjunction of vitamin C. The relative contents of metabolic reactions and phase I metabolites in each biosample are shown in Table 1 , which were calculated by summing the relative contents of all metabolites generated through it and all phase I metabolites, respectively. In urine, the contents of sulfation metabolites, glucuronidation metabolites and vitamin C conjugates were 74.60%, 25.83% and 1.08%, respectively. In feces, the contents of sulfation metabolites, glucuronidation metabolites and vitamin C conjugates were 73.53%, 1.62% and 15.54%, respectively. This indicated that medicarpin was mainly excreted in the form of sulfates. In plasma, the major metabolic reaction was glucuronidation (relative content: 67.87%). The glycosylation metabolite (M50) was only found in urine. Furthermore, the contents of phase I metabolites of medicarpin in most biosamples were very low (<10%), except in the colon (17.57%), which suggested that phase II metabolites are major metabolites. Figure 14 . The distribution of 165 metabolites of medicarpin and their relative contents in 13 biosamples ( a , new compounds). The relative content of a metabolite in each biosample was calculated by (peak area of a metabolite/total peak area of all detected metabolites) × 100%. Figure 14 . The distribution of 165 metabolites of medicarpin and their relative contents in 13 biosamples ( a , new compounds). The relative content of a metabolite in each biosample was calculated by (peak area of a metabolite/total peak area of all detected metabolites) × 100%. 
